BIT225: Additional Phase II data
Additional data from treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all patients with HCV genotype 3 infection who received twice-daily BIT225 plus peginterferon alfa-2b and ribavirin for 28 days achieved undetectable HCV RNA levels at week 24. The trial enrolled 8 patients with HCV genotype 3 infection and 4 patients with HCV genotype 1a infection. Patients received twice-daily 300 mg BIT225 plus peginterferon alfa-2b and ribavirin for 28 days, preceded by 7 days of peginterferon alfa-2b and ribavirin alone. Patients remained on peginterferon alfa-2b and ribavirin for a total of 48 weeks and received antiretroviral therapy (ART) throughout the trial. Biotron reported interim 12-week data from the trial last year (see BioCentury, Dec. 9, 2013). ...